| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/25/2010 | US20100047231 Immuno-Stimulant Combination for Prophylaxis and Treatment of Hepatitis C |
| 02/25/2010 | US20100047230 Anti her2/neu antibody |
| 02/25/2010 | US20100047208 Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof |
| 02/25/2010 | US20100047204 Use of organic compounds |
| 02/25/2010 | US20100047188 Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| 02/25/2010 | US20100047179 Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production |
| 02/25/2010 | US20100047178 Perylenequinone derivatives and uses thereof |
| 02/25/2010 | US20100047169 NK Cell Receptor Conjugates for Treating Malignancies |
| 02/25/2010 | US20100047168 Soluble Zcytor 11 Cytokine Receptors |
| 02/25/2010 | US20100047166 Antibodies and related molecules that bind to 58p1d12 proteins |
| 02/25/2010 | US20100047164 Anti-Tumor Antibodies |
| 02/25/2010 | US20100047162 Methods of processing multi-phasic dispersons |
| 02/25/2010 | DE202009002058U1 Lebendimpfstoffzusammensetzung Live vaccine composition |
| 02/25/2010 | CA2734866A1 Complement inhibitors for treatment of injury from intracerebral hemorrhage |
| 02/25/2010 | CA2734838A1 T cell receptors and related materials and methods of use |
| 02/25/2010 | CA2734800A1 Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe) |
| 02/25/2010 | CA2734755A1 Treatment and/or prevention of peanut induced anaphylaxis |
| 02/25/2010 | CA2734654A1 An immunological composition comprising sulpholipo-cyclodextrin and saponin |
| 02/25/2010 | CA2734645A1 Engineered anti-il-13 antibodies, compositions, methods and uses |
| 02/25/2010 | CA2734643A1 Avian influenza virus antigen, and booster immunization method for avian influenza vaccine in combination with mucosal adjuvant which is effective through oral administration |
| 02/25/2010 | CA2734585A1 Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| 02/25/2010 | CA2734515A1 Inhbb epitope peptides and vaccines containing the same |
| 02/25/2010 | CA2734467A1 Hig2 and urlc10 epitope peptide and vaccines containing the same |
| 02/25/2010 | CA2734358A1 Treatment of an autoimmune disease using il-18 antagonists |
| 02/25/2010 | CA2734265A1 Dock-and-lock (dnl) vaccines for cancer therapy |
| 02/24/2010 | EP2157192A1 Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (R-Spondins) |
| 02/24/2010 | EP2157173A1 An avian embryo particulate biomass for the production of virus antigens |
| 02/24/2010 | EP2157102A1 Antibodies against tenascin-C |
| 02/24/2010 | EP2156845A1 Combined vaccines comprising hepatitis B surface antigen and other antigens |
| 02/24/2010 | EP2156844A1 AGENT EXHIBITING PROPERTIES TO FORM THE CELLULAR IMMUNITY AGAINST MYCOBACTERIUM TUBERCULOSIS H37 Rv, METHOD FOR THE PRODUCTION THEREOF (VARIANTS), A RECOMBINANT STRAIN AND AN AGENT FOR TUBERCULOSIS DIAGNOSIS |
| 02/24/2010 | EP2155872A1 Tem8 peptides and vaccines comprising the same |
| 02/24/2010 | EP2155791A1 Humanized and chimeric anti-trop-2 antibodies that mediate cancer cell cytotoxicity |
| 02/24/2010 | EP2155783A2 Cross-species-specific cd3-epsilon binding domain |
| 02/24/2010 | EP2155782A2 Mhc peptide complexes and uses thereof in infectious diseases |
| 02/24/2010 | EP2155691A1 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| 02/24/2010 | EP2155250A1 Carbohydrate-containing pan cancer marker |
| 02/24/2010 | EP2155249A1 Compositions and methods for diagnosing and treating cancer |
| 02/24/2010 | EP2155248A1 Targeting abcb5 for cancer therapy |
| 02/24/2010 | EP2155247A1 Prevention of staphylococcus biofilm formation |
| 02/24/2010 | EP2155245A1 Chlamydia vaccine |
| 02/24/2010 | EP2155244A2 Antigenic polysaccharides and process for their preparation |
| 02/24/2010 | EP2155243A2 Compositions and methods comprising klk3, psca, or folh1 antigen |
| 02/24/2010 | EP2155190A2 Topical formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice with multiple modes of action |
| 02/24/2010 | EP1471936B1 Hiv vaccine and method of use |
| 02/24/2010 | EP1325130B1 Nogo receptor homologs |
| 02/24/2010 | EP1112087B1 Hedgehog and patched antagonists for inhibiting cell and tissue growth and differentiation and uses therefor |
| 02/24/2010 | EP1007084B1 Immunogenic lhrh compositions and methods relating thereto |
| 02/24/2010 | EP0861261B9 Nucleotide and protein sequences of vertebrate delta genes and methods based thereon |
| 02/24/2010 | EP0837696B1 Improved delivery of diagnostic and therapeutic agents to a target site |
| 02/24/2010 | CN101657215A Pharmaceutical composition, comprising an anti-CD6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis |
| 02/24/2010 | CN101657214A Treatment or prophylaxis of asthma |
| 02/24/2010 | CN101657213A A method for enhancing t cell response |
| 02/24/2010 | CN101654479A Mammalian receptor proteins, agents, and methods relating thereto |
| 02/24/2010 | CN101653604A Anti-ngf antibodies for the treatment of various disorders |
| 02/24/2010 | CN101653603A Peptides and antibodies binding to anionic phospholipids and aminophospholipids and their use in treating disease |
| 02/24/2010 | CN101653602A Treatment, prophylaxis and diagnostic reagent of hepatitis b |
| 02/24/2010 | CN101653601A Livestock peptide vaccine and preparation method thereof |
| 02/24/2010 | CN100591762C Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| 02/24/2010 | CN100591759C Animal protein free media for cultivation of cells |
| 02/24/2010 | CN100591694C Igy antibody and method for selectively separating it from eggs of anseriformes |
| 02/23/2010 | US7667088 bioassay; induction of antibodies against desmoglein; activation of lymphocytes; oral diseases |
| 02/23/2010 | US7667021 Neutralizing human anti-IGFR antibody |
| 02/23/2010 | US7667020 Nucleotide sequence coding receptor protein for detecting moderator of autoimmune disease; treat, prevent, or delay a tissue proliferation-associated disorder as rheumatoid arthritis and multiple sclerosis |
| 02/23/2010 | US7667018 A gene (designated 161P2F10B) and its encoded protein which exhibits tissue specific expression in normal adult tissue and is aberrantly expressed in the cancers; medical diagnostis;, prognosis, prophylactis and/or gene therapy; tissue-target therapy; used to elicit a humoral or cellular immune response |
| 02/23/2010 | US7667015 Genetic engineering; induce immunology response; biodrug as anticarcinogenic agents, for pancreatic cancer |
| 02/23/2010 | US7667007 αvβ3-specific antibodies |
| 02/23/2010 | US7667006 Anti-HIV antibody |
| 02/23/2010 | US7666999 Neutral amino acid transporter and gene thereof |
| 02/23/2010 | US7666998 Cell growth inhibitor containing anti-PepT antibody |
| 02/23/2010 | US7666993 Immunotherapy of prostate, including hormone-refractory prostate cancer (HRPC), and breast cancer; vaccines |
| 02/23/2010 | US7666988 BASB082 Polypeptides |
| 02/23/2010 | US7666985 HLA-A24-restricted cancer antigen peptides |
| 02/23/2010 | US7666674 Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| 02/23/2010 | US7666669 Polypeptide |
| 02/23/2010 | US7666626 P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi) |
| 02/23/2010 | US7666624 Chemically conjugating a peptide of interest to a heterologous peptide that has been expressed on the coat protein of a cowpea mosaic virus to generate a conjugate and administering the conjugate to a host animal to increase the level of TH1-type immune response |
| 02/23/2010 | US7666621 Has an apparent molecular weight of 42,000 Daltons; fusion protein of the protein D bound to a polypeptide, carbohydrate, or matrix; prepared by providing a non-human host containing a plasmid or phage comprising a DNA nucleotide sequence and expressing the encoded protein D |
| 02/23/2010 | US7666619 Compounds and methods for regulating bacterial growth and pathogenesis |
| 02/23/2010 | US7666605 Method for prognostic evaluation of carcinoma using anti-P-LAP antibody |
| 02/23/2010 | US7666582 Immunoglobulin G-degrading enzyme for use as tool in diagnosis, prevention and treatment of streptococcal infection |
| 02/23/2010 | US7666581 Complexing antigenic proteins/peptides; membrane proteins; tumor associated antigens |
| 02/23/2010 | US7666441 Nucleic acids encoding peptides having at least one biological activity of Can f I or Can f II, protein allergens of the species Canis familiaris; suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander |
| 02/23/2010 | US7666440 Dermatomycosis vaccine |
| 02/23/2010 | US7666439 Also contains an antigen of swine influenza virus, porcine reproductive and respiratory syndrome virus, or porcine circovirus; an acrylic acid polymer, metabolizable oil and an oxyethylene-oxypropylene block polymer as adjuvant |
| 02/23/2010 | US7666438 Generating an immune response by administering to a host an immunologically effective amount of an isolated fibrinogen binding domain of the clumping factor A protein (ClfA) from Staphylococcus aureus and an immunologically effective amount of an isolated S. aureus capsular polysaccharide type 5 |
| 02/23/2010 | US7666437 Containing a terminal cysteine, wherein when administered by intranasal route to mammals, it generates an immune response in Peyer patches, inguinal, cervical lymphatic ganglions and in the spleen that confers protection from illness caused by enterotoxigenic Escherichia Coli |
| 02/23/2010 | US7666436 Pertussis toxin mutants, Bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines |
| 02/23/2010 | US7666435 Treatment of fine wrinkles with clostridia neurotoxins |
| 02/23/2010 | US7666434 Screening blood and identifying immunologically active antigen of herpes simplex virus (HSV) which attacks skin; diagnosing viral infection; viricides |
| 02/23/2010 | US7666433 Recombinant RSV strains with altered G protein |
| 02/23/2010 | US7666432 Suppressing fibrosis in a mammal having a fibrosing disease by administering a Serum Amyloid P (SAP) protein; treatment of diseases such as scleroderma, pulmonary fibrosis and asthma |
| 02/23/2010 | US7666431 Compositions and methods for the inhibition of membrane fusion by paramyxoviruses |
| 02/23/2010 | US7666430 Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein |
| 02/23/2010 | US7666429 Nucleic acids encoding a house dust mite allergen Der P III, and uses therefor |
| 02/23/2010 | US7666428 Recombinant allergen with reduced IgE binding but undiminished T-cell antigenicity |
| 02/23/2010 | US7666427 Plasmid DNA or viral vector vaccine including components from different clades of Env and Gag-Pol-Nef from a single clade; multiclade HIV envelope immunogen |
| 02/23/2010 | US7666426 Method for immune response eliciting in a mammal |
| 02/23/2010 | US7666425 Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen |
| 02/23/2010 | US7666424 Directed against a target antigen, cell culture to express, code the protein, for treating cancer |
| 02/23/2010 | US7666423 Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |